Literature DB >> 17682128

The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.

Murat Oz1, Keun-Hang Yang, Meral Dinc, Toni S Shippenberg.   

Abstract

The effect of the endogenous cannabinoid anandamide on K(+) currents activated by the ATP-sensitive potassium (K(ATP)) channel opener cromakalim was investigated in follicle-enclosed Xenopus oocytes using the two-electrode voltage-clamp technique. Anandamide (1-90 microM) reversibly inhibited cromakalim-induced K(+) currents, with an IC(50) value of 8.1 +/- 2 microM. Inhibition was noncompetitive and independent of membrane potential. Coapplication of anandamide with the cannabinoid type 1 (CB(1)) receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR 141716A) (1 microM), the CB(2) receptor antagonist N-[(1S)endo-1,3,3-trimethyl bicyclo heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) (1 microM), or pertussis toxin (5 microg/ml) did not alter the inhibitory effect of anandamide, suggesting that known cannabinoid receptors are not involved in anandamide inhibition of K(+) currents. Similarly, neither the amidohydrolase inhibitor phenylmethylsulfonyl fluoride (0.2 mM) nor the cyclooxygenase inhibitor indomethacin (5 microM) affected anandamide inhibition of K(+) currents, suggesting that the effects of anandamide are not mediated by its metabolic products. In radioligand binding studies, anandamide inhibited the specific binding of the K(ATP) ligand [(3)H]glibenclamide in the oocyte microsomal fractions, with an IC(50) value of 6.3 +/- 0.4 microM. Gonadotropin-induced oocyte maturation and the cromakalim-acceleration of progesterone-induced oocyte maturation were significantly inhibited in the presence of 10 microM anandamide. Collectively, these results indicate that cromakalim-activated K(+) currents in follicular cells of Xenopus oocytes are modulated by anandamide via a cannabinoid receptor-independent mechanism and that the inhibition of these channels by anandamide alters the responsiveness of oocytes to gonadotropin and progesterone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682128     DOI: 10.1124/jpet.107.125336

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.

Authors:  Christopher J Lynch; Qing Zhou; Show-Ling Shyng; David J Heal; Sharon C Cheetham; Keith Dickinson; Peter Gregory; Michael Firnges; Ulrich Nordheim; Stephanie Goshorn; Dania Reiche; Lechoslaw Turski; Jochen Antel
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

4.  Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.

Authors:  Guillermo B Silva; Douglas K Atchison; Luis I Juncos; Néstor H García
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

5.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

6.  The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.

Authors:  Keun-Hang Yang; Sehamuddin Galadari; Dmytro Isaev; Georg Petroianu; Toni S Shippenberg; Murat Oz
Journal:  J Pharmacol Exp Ther       Date:  2010-02-16       Impact factor: 4.030

7.  Cannabinoid interactions with ion channels and receptors.

Authors:  Abeline Rose Watkins
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

Review 8.  Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.

Authors:  José Antonio Estrada; Irazú Contreras
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

9.  Potassium channels as molecular targets of endocannabinoids.

Authors:  Yu-Fung Lin
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.